Clinical trial
Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia
NCT00304993 · Foundation Research, Florida, Other · Completed
Key facts
| NCT number | NCT00304993 |
|---|---|
| Title | Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia |
| Official title | Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia |
| Lead sponsor | Foundation Research, Florida, Other |
| Collaborators | GlaxoSmithKline Industry Kos Pharmaceuticals Abbott |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Metabolic Syndrome X, Insulin Resistance |
| Intervention type | Drug |
| Interventions | fenofibrate, niacin, rosiglitazone |
| Enrollment | 30 |
| Start date | Jan 1, 2001 |
| Completion | Feb 1, 2005 |
| First posted | Mar 21, 2006 |
| Last update posted | Mar 21, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: